Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Michela Terlizzi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

M. Terlizzi1, R. Sorrentino1, C. Colarusso2, A. Molino1, A. Saccomanno2, R.P. Aquino2, A. Pinto2

Author affiliations

  • 1 Department Of Pharmacy, University of Salerno, 84084 - Fisciano /IT
  • 2 Department Of Pharmacy, University of Salerno, 84084 - Fisciano/IT
More

Resources

Abstract 5673

Background

Lung cancer is the leading cancer-related death disease worldwide. This alerting data is mainly due to late diagnosis of lung cancer, especially non-small cell-lung cancer (NSCLC), limiting the therapeutic options. Therefore, the identification of non-invasive, selective, sensitive and specific biomarker/s represents the emerging medical need for the clinical practice to avoid late diagnosis and ameliorate the personalized therapy with an ensuing higher survival rate. It is well known that smoking and chronic obstructive pulmonary disease represent two high risk factors for NSCLC. Therefore, in this study we aimed to evaluate the levels of a novel diagnostic tool for NSCLC patients in order to understand whether caspase-4 could represent a predictive biomarker.

Methods

In order to evaluate the circulating caspase-4 in the blood, we developed an ELISA test.

Results

Smokers (≥15 cigarettes/day) had higher levels of circulating caspase-4 (95% CI, 1.331-1.94 ng/ml) than healthy subjects (95% CI, 0.395-0.619 ng/ml). Though, these levels were statistically lower than those observed in NSCLC patients. Moreover, there were no statistical differences between the levels of circulating caspase-4 in smokers younger or older than 60 years. Similarly, no gender differences were noted. Similarly, COPD patients, who are smokers and former smokers, had higher levels of circulating caspase-4 (95% CI, 1.703-2.995 ng/ml). According to χ2 test, the expected frequency of smokers, positive to the circulating caspase-4, who could develop NSCLC is robustly significant (calculated χ2=82.884 vs tabulated χ2=3.845, df = 1). Moreover, according to the independence test, smoker who were positive to the circulating caspase-4 are at high risk to develop NSCLC.

Conclusions

In conclusion, we report for the first time that the circulating caspase-4 could represent a predictive diagnostic tool to avoid the occurrence of NSCLC.

Clinical trial identification

Legal entity responsible for the study

ImmunePharma s.r.l.

Funding

Italian Ministry of Economy (MISE) Invitalia.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings